NASDAQ:CERO CERo Therapeutics Q2 2024 Earnings Report $0.01 +0.00 (+18.18%) As of 01:21 PM Eastern ProfileEarnings HistoryForecast CERo Therapeutics EPS ResultsActual EPS-$660.00Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACERo Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACERo Therapeutics Announcement DetailsQuarterQ2 2024Date8/14/2024TimeN/AConference Call DateN/AConference Call TimeN/AUpcoming EarningsCERo Therapeutics' next earnings date is estimated for Wednesday, September 2, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile CERo Therapeutics Earnings HeadlinesCERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following TreatmentJune 15 at 8:15 AM | globenewswire.comCERo Therapeutics Raises Funding via Convertible Note FinancingMay 29, 2026 | tipranks.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.June 15 at 1:00 AM | Banyan Hill Publishing (Ad)CERo Therapeutics Holdings Inc. WtMay 20, 2026 | barrons.comCERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 TrialMay 11, 2026 | globenewswire.comCERo Therapeutics Secures Convertible Note Financing FacilityApril 14, 2026 | tipranks.comSee More CERo Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CERo Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CERo Therapeutics and other key companies, straight to your email. Email Address About CERo TherapeuticsCERo Therapeutics (NASDAQ:CERO), an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead program in hematologic malignancies targets an Eat Me signal upregulated on B cell and myeloid tumors. The company is based in South San Francisco, California.View CERo Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Dividend Increases Investors Can Actually TrustAdobe Stock Just Got Cheaper—Is Wall Street Missing the Story?Viasat's Orbiting Profits: Space Force Jackpot?What to Expect From Q2 Earnings as Tech Strength BroadensTJX: Retail’s Apex Predator Feasts on InflationForget AI for a Moment, This Homebuilder Is Stealing the ShowWhy Oracle's 10% Drop May Be Telling the Wrong Story Upcoming Earnings Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
